Jeffrey Fudin
Jeffrey Fudin
Dr. Jeff Fudin graduated from Albany College of Pharmacy & Health Sciences with a bachelor's degree and PharmD. He is a Diplomate to the American Academy of Pain Management, a Fellow to ACCP, a Fellow to ASHP, and a member of several other professional organizations. He is founder and CEO of Remitigate, LLC (, a software platform for interpreting urine drug screens (Urintel) and pharmacogenetics(Phenotel). Dr. Fudin is a section editor for Pain Medicine and serves on the editorial board for Practical Pain Management. He is founder/chairman of Professionals for Rational Opioid Monitoring & Pharmacotherapy (PROMPT), an advocacy group in favor of safe opioid prescribing. He practices as a clinical pharmacy specialist (WOC) and director of PGY-2 pharmacy pain residency programs at the Stratton Veterans Administration Medical Center in Albany, New York. He is an adjunct associate professor of pharmacy practice at Western New England University College of Pharmacy and Albany C

Closing the Loop on Abuse-Deterrent Opioids

MAY 19, 2016
With the new extended-release (ER) oxycodone that meets all 3 FDA requirements for abuse-deterrent labeling, and even more novel products on the way, pharmacists are in a unique position to assess patients’ risks and then qualify them for specific opioids.
Considering the new CDC guidelines for opioid prescribing for chronic pain, there’s a lot at stake for prescribers, pharmacists, and patients alike. This article will take us from abuse-deterrent formulations (ADFs), to product-specific attributes, to the burgeoning role of pharmacists as providers.

ER vs. IR
ER opioid formulations are attractive options for drug abusers because they contain relatively large doses intended to be released over an extended period of time. However, manipulation by chewing, crushing, or dissolving can release the drug more rapidly, a phenomenon known as “dose dumping.”1

Immediate-release (IR) opioids are associated with wider fluctuations in serum levels. The peaks are linked to an increased risk for dose-related complications, including sedation and respiratory depression, while the troughs are associated with recurrence variation in pain control and increased risk for pseudoaddiction and hyperalgesia.2,3 In comparison, ER formulations provide steady levels over time and less fluctuation.

Unfortunately, when ER formulations are manipulated, they can lose their timed-release profile and behave similarly to IR formulations by releasing the drug rapidly. 

As a result of increased awareness of toxicities and deaths due to manipulation of ER formulations, there has been a parallel surge of IR prescriptions and decline in ER prescriptions. For instance, prescriptions for ER oxycodone declined from 7.3 million in 2010 to 4.7 million in 2014, while prescriptions for IR oxycodone increased from 10.4 million to 15.8 million in the same period.4


Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?

Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Next-Generation Pharmacist® Awards

3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference

Personalize the information you receive by selecting targeted content and special offers.